Tenax Therapeutics (TENX)
Develops oral levosimendan in Phase 3 trials for PH-HFpEF.
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $TENX--TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law.
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
A single clinical readout drove Tenax Therapeutics (NASDAQ: TENX) shares down approximately 84% to 85% shareholder after the Company disclosed that its Phase 3
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
NEW YORK--(BUSINESS WIRE)--A single clinical readout drove Tenax Therapeutics (NASDAQ: TENX) shares down approximately 84% to 85% shareholder after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. If you held TENX shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The.
Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)
Tenax Therapeutics shareholders were left holding a substantially lower-valued stock after the Phase 3 LEVEL readout for TNX-103 -- and those losses may carry legal rights. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- A single disclosure erased approximately 84% to 85% of Tenax Therapeutics (NASDAQ: TENX) shareholder value when the Company announced that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints.
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case
Tenax Therapeutics NASDAQ: TENX reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemodynamic findings will inform its next steps in the program.
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback
Tenax Therapeutics Inc. (NASDAQ:TENX) stock is trading lower on Monday after the company reported topline results from its Phase 3 LEVEL study evaluating oral levosimendan (TNX-103) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript
Tenax Therapeutics' heart drug misses main goal in study, shares plunge
Tenax Therapeutics said on Monday its experimental heart drug failed to meet the main goal of a late-stage study.
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended June 30, 2026 and provided an update on its corporate progress.
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know
The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead
Tenax Therapeutics, Inc. is downgraded from Buy to Hold ahead of a major August 2026 phase 3 data readout for TNX-103 in PH-HFpEF. TNX-103 targets a large, unmet market with no approved therapies, but phase 3 success is uncertain despite promising phase 2 secondary endpoint results relating to 6MWD. The phase 3 LEVEL study is powered >90% to detect a 25-meter 6MWD change, but failure could cut TENX shares by 50% or more.
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that results from the Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026, being held August 28-31 in Munich, Germany.
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team with appointments of Thomas Staab as Chief Financial Officer and Timothy Healey, MBA, as Chief Commercial Officer CHAPEL HILL, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the quarter ended March 31, 2026 and provided an update on its recent corporate progress.
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R.
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200-Day Moving Average – What’s Next?
Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $10.78 and traded as high as $16.95. Tenax Therapeutics shares last traded at $16.00, with a volume of 557,161 shares trading hands. Analyst Upgrades
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?
Shares of Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $10.43 and traded as high as $14.24. Tenax Therapeutics shares last traded at $13.23, with a volume of 354,937 shares traded. Analysts Set New Price Targets